Most FDA-approved bsTCEs typically incorporate a CD3-targeting domain to stimulate T-cell signaling enabling the discharge of cytotoxic agents, effectively overcoming the issue of diminished tumor antigen presentation caused by MHC downregulation on tumor cells. This evidence concerns the gene HLA-C and neoplasm.